The Bridge Program Welcomes Vetter, StrandnBerg and Therapeutic Innovation Australia as New Consortium Partners and reintroduces UNSW as university partner
18 June 2025 –
The Bridge Program is proud to announce the addition of Vetter, StrandnBerg, UNSW and Therapeutic Innovation Australia (TIA) to its consortium of partners for 2025. These strategic partnerships will further strengthen the program’s mission to equip Australian researchers and professionals with the skills, knowledge, and networks needed to commercialise new medicines.
The Bridge Program, delivered by Queensland University of Technology (QUT), is a year-long, industry led initiative designed to train researchers, clinicians, and professionals in navigating the complex pharmaceutical and biotech commercialisation pathway. Each year, up to 100 participants from across Australia are selected to undertake interactive online learning modules, attend networking events, and participate in seminars featuring high-profile industry speakers. The program covers the scientific, legal, financial, clinical, regulatory, and reimbursement aspects essential for bringing new medicines to market and is supported by a consortium that includes leading pharmaceutical companies, universities, and industry affiliates.
They join an esteemed consortium of leaders in the pharmaceutical industry to translate skills and knowledge to bridge the gap between academia and industry – AbbVie, Amgen, AstraZeneca, Moderna, Pfizer, Roche and university partners UWA and QUT.
Vetter, an internationally recognised CDMO (contract development and manufacturing organisation) headquartered in Germany, with a global fill&finish manufacturing footprint for early stage and commercial demand and market support footprint, brings a wealth of global expertise in aseptically pre-filled injectables and drug delivery systems to the consortium. Vetter is specialised to handle complex novel biologics including ophthalmics. Their involvement will offer Bridge Program participants unique insights into international best practices and trends in the biopharmaceutical sector.
StrandnBerg, a consulting firm specialising in biotechnology and medical technology in Australia, provides deep technical and commercialisation expertise. This includes drug development advice and expertise (with experience taking products from inception to market launch), as well as strategic planning and business progression through their strong networks in the sector and globally. Their deep networks and understanding of pathways to market will provide participants with insights and knowledge to help bring their ideas and products to market quicker.
Therapeutic Innovation Australia, a leading national research infrastructure provider, is dedicated to accelerating the translation of Australian health and medical research. TIA’s participation will further enhance the program’s commitment to fostering innovation and supporting the development of new therapeutics across the country.
In addition to the industry consortium additions, UNSW will also rejoin the university partners of the program, reaffirming their commitment to advancing innovation and collaboration in both engineering and medicine. With the active involvement of UNSW’s Faculty of Science and Faculty of Health and Medicine, this renewed partnership will strengthen the program’s multidisciplinary approach, drawing on UNSW’s world-class research expertise and industry connections.
“We are delighted to welcome Vetter, StrandnBerg, Therapeutic Innovation Australia and UNSW to the Bridge Program consortium,” said program director Distinguished Professor Lyn Griffiths AM. “Their expertise and commitment to advancing pharmaceutical innovation will provide invaluable opportunities for our community, helping to shape the future of Australia’s pharmaceutical and biotech industries.”
For more information about the Bridge Program and its partners, please visit https://research.qut.edu.au/bridge/
For more information about the Bridge Program and its partners, please visit our partner page.
 |
 |
 |
 |